Abstract

Ferrets are widely used to study human influenza virus infection. Their airway physiology and cell receptor distribution makes them ideal for the analysis of pathogenesis and virus transmission, and for testing the efficacy of anti-influenza interventions and vaccines. The 2009 pandemic influenza virus (H1N1pdm09) induces mild to moderate respiratory disease in infected ferrets, following inoculation with 10^6 plaque-forming units (pfu) of virus. We have demonstrated that reducing the challenge dose to 10^2 pfu delays the onset of clinical signs by 1 day, and results in a modest reduction in clinical signs, and a less rapid nasal cavity innate immune response. There was also a delay in virus production in the upper respiratory tract, this was up to 9-fold greater and virus shedding was prolonged. Progression of infection to the lower respiratory tract was not noticeably delayed by the reduction in virus challenge. A dose of 10^4 pfu gave an infection that was intermediate between those of the 10^6 pfu and 10^2 pfu doses. To address the hypothesis that using a more authentic low challenge dose would facilitate a more sensitive model for antiviral efficacy, we used the well-known neuraminidase inhibitor, oseltamivir. Oseltamivir-treated and untreated ferrets were challenged with high (10^6 pfu) and low (10^2 pfu) doses of influenza H1N1pdm09 virus. The low dose treated ferrets showed significant delays in innate immune response and virus shedding, delayed onset of pathological changes in the nasal cavity, and reduced pathological changes and viral RNA load in the lung, relative to untreated ferrets. Importantly, these observations were not seen in treated animals when the high dose challenge was used. In summary, low dose challenge gives a disease that more closely parallels the disease parameters of human influenza infection, and provides an improved pre-clinical model for the assessment of influenza therapeutics, and potentially, influenza vaccines.

Introduction

In April 2009, a novel H1N1 influenza A virus of swine origin emerged from North America and spread around the world, resulting in the first influenza pandemic of the 21st century [1]. The pandemic H1N1 virus (H1N1pdm09) contained a unique constellation of genes derived from North American triple-reassortant swine influenza and Eurasian swine influenza, and was antigenically unrelated to the seasonal H1N1 virus circulating in the human population prior to that time [2]. Infection resulted predominantly in a mild disease, but developed into severe illness associated with mortality in a minority of cases [3,4]; the global mortality has been estimated as 300,000 [5]. H1N1pdm09 virus is now established worldwide as a seasonal infection, and has fully replaced the previous seasonal H1N1 virus.

The ferret model for influenza infection is often referred to as the “gold standard” model since these animals display several key attributes considered to be predictive of disease severity observed in human influenza infection [6,7]. Ferrets are susceptible to human influenza virus isolates without requiring prior adaptation of the viruses, develop clinical signs similar to those in human infections (such as fever, sneezing and lethargy), possess a similar respiratory tract physiology, and have α-2,6 and α-2,3-linked sialic acid virus receptors with a distribution similar to that in the human respiratory tract [8]. Infection of ferrets via the intra-nasal route with H1N1pdm09 virus has typically induced a mild to moderate, nonlethal infection resulting in weight loss, transient pyrexia, and mild upper respiratory tract signs. These studies have typically used a dose of 10^6 TCID_{50} per ferret in order to ensure all ferrets become infected [9–12]. However this dose is a gross exaggeration
of the dose which is required to infect humans (0.6–3 TCID_{50} by aerosol challenge) [13,14], and ferrets are susceptible to much lower doses of influenza viruses than 10^6 TCID_{50}. For example, 50% ferret infectious doses (FID_{50}) have been estimated to be as low as 10–30 TCID_{50} for pre-pandemic H1N1 viruses, 3 plaque-forming units (pfu) for an H1N1pdm virus, 1–2 pfu for an H5N2 virus and 4 pfu for an H5N1 virus [15–17]. Use of high dose inocula may enhance pathogenicity and accelerate infection kinetics, which may obscure the effects of antiviral interventions. It has been shown, for example, that a high dose of influenza A virus (10^6.8 EID_{50}) overcame the protective effect of a defective interfering virus preparation, which was fully protective in mice when a lower challenge dose (10^3.5 EID_{50} virus) was used [18]. This consideration is particularly relevant for the ferret model of influenza, as these animals have been used extensively in demonstrating the efficacy of anti-influenza drugs such as the neuraminidase inhibitors oseltamivir, zanamivir and peramivir [12,19–23].

The A/California/04/2009 isolate of H1N1pdm09 virus (Cal/04) was isolated early in the pandemic from a non-fatal infection in a 10 year old boy [24]. When compared to other H1N1pdm09 isolates in the ferret model, Cal/04 induced only mild disease, and is thus a suitable model virus for typical human H1N1pdm09 infections [9,25]. A challenge dose of only 100 pfu Cal/04 has been used previously in our laboratory to infect ferrets intranasally [26,27]. The purpose of this study was to further characterize the influenza infection model using a low dose (100 pfu) of the Cal/04 strain, to compare the kinetics and severity of infection with this dose to higher doses (10^4 or 10^6 pfu) delivered by the same route, and to determine if the size of infectious dose had an effect on the observed antiviral activity of standard oseltamivir treatments.

**Methods**

**Animals**

Ferrets (*Mustela putorius furo*) were obtained from Highgate Farm, UK, and confirmed as seronegative for influenza H1N1pdm09 antibodies by haemagglutination-inhibition assay before experiments commenced. Mean weight at challenge was approximately 950 g (range 707–1367 g), and either females (3 experiments; age range 6–12 months) or males (1 experiment; age range 3–4 months) were used. An identifier chip (IDENTICHIP, Bio-Thermo) was inserted subcutaneously into the dorsal cervical region of each animal. Animals were monitored for signs of disease twice daily (approximately 8 hr apart), and weight and temperature were recorded once or twice daily, respectively. Animals were sedated by intramuscular injection of ketamine/xylazine (17.9 mg/kg and 3.6 mg/kg bodyweight), prior to intranasal instillation of challenge virus (routinely 0.2 ml total, 0.1 ml per nostril) diluted in phosphate buffered saline (PBS). Nasal washes were obtained using 2 ml PBS [28]. At various times post-infection, ferrets were anaesthetised, exanguinated by cardiac puncture, and tissue samples were collected. The experimental animal work described here was scrutinized and approved by the Animal Welfare and Ethical Review Body of Public Health England (Porton), as required by the UK Home Office Animals (Scientific Procedures) Act, 1986. The premises in which the work was conducted are approved under Home Office Certificate of Designation PCD70/1707.

**Clinical scoring**

The most frequently observed clinical signs of disease were sneezing, nasal discharge and inactivity (lethargy), each of which was monitored twice daily. For each ferret in each observation period, a score of 0 or 1 was assigned for the absence or presence, respectively, of sneezing or nasal discharge. Activity was scored as 0 = normal activity, 1 = reduced activity, and 2 = inactive. All scores were summed for each ferret over the period of observation (starting from the day of inoculation), divided by the number of days, and averaged for the treatment group to give a mean score per ferret per day. Viable cells in nasal washes were counted by addition of 1/10 volume 0.4% Trypan Blue (Sigma), using a haemocytometer.

**Virus**

Influenza A/California/04/09 (H1N1) was obtained from the Centers for Disease Control and Prevention (CDC, Atlanta, USA), and propagated in Madin-Darby Canine Kidney (MDCK) cells, obtained from European Collection of Cell Cultures (ECACC, Porton Down, UK). The identity of the virus was confirmed by sequencing the HA and NA genes. Virus titres were determined by plaque assay on MDCK cells under an agar overlay, followed by staining with crystal violet.

**Oseltamivir treatment**

In two experiments, ferrets were treated with oseltamivir (Tamiflu, Roche). The drug was dissolved in sterile water to 12 mg/ml, and delivered to ferrets by oral gavage twice daily. Doses of 5 mg/kg/day and 10 mg/kg/day are equivalent to human doses of 75 and 150 mg/day, respectively [29], and represent prophylactic and therapeutic doses. Prophylactic dosing commenced 2 hr prior to infection; therapeutic dosing commenced 6 hr post-infection. In both experiments, dosing continued for 5 days.

**Quantitative real-time reverse transcriptase PCR (qRT-PCR)**

Total RNA was extracted from ferret tissues, which had been collected into RNALater (Qiagen) and stored at −20°C (lung and trachea), or frozen at −80°C (nasal turbinate), using the Qiagen RNeasy Mini kit (lung) or RNeasy Fibrous kit (trachea, nasal turbinates). Lung samples were taken from the upper left lobe in each case. RNA was quantified spectrophotometrically using a Nanodrop ND-1000. RNA quality was assessed using an Agilent 2100 Bioanalyzer. Absolute quantification of influenza virus segment 7 was determined using a quantified, negative-sense synthetic T7 RNA polymerase transcript, from a full-length plasmid clone of Cal/04 segment 7, to construct a standard curve. Reactions used primers (M+E24, M+124Mod) and probe (M+64 with 5’-FAM and 3’-BHQ1) as described [30,31] with the Superscript III Platinum One-Step qRT-PCR kit (Invitrogen), and were analysed using the ABI Prism 7900HT and SDS 2.4 software (Applied Biosystems).

**Pathological studies**

Samples of nasal cavity, trachea and lung were fixed in 10% neutral buffered formalin, and processed routinely to paraffin wax. Sections of 4–6 μm were stained with haematoxylin and eosin (HE) for examination by light microscopy. For the therapeutic oseltamivir study, the severity of changes in each section was scored subjectively, as minimal, mild, moderate, or marked. The sections were examined “blind” to eliminate observer bias.

**Statistical methods**

Advice was obtained from a qualified statistician. Differences between groups were assessed for statistical significance using the
Mann-Whitney U-test at a level of $p<0.05$. Means of logarithmic data were calculated and plotted as geometric mean. Area under the curve was calculated by numerical integration using the trapezoidal rule.

**Results**

Low dose challenge leads to delayed clinical disease kinetics and increases virus shedding

Ferrets were infected with Cal/04 by the intra-nasal route with the widely used high dose (10^6 pfu per ferret), a medium dose (10^4 pfu), or a low dose (10^2 pfu), and disease progression was monitored for up to 14 days post-infection (dpi). The results of the clinical findings are shown in Table 1. All challenged animals demonstrated clinical signs of disease, which were not observed in mock-infected animals, including transiently elevated temperature, transient weight loss, sneezing, nasal discharge, and inactivity, although not all signs were observed in every animal. The most notable effect of reducing the virus inoculum from 10^6 pfu to 10^2 pfu was to delay the progression of disease by approximately 1 day, with a dose of 10^4 pfu giving an intermediate delay. This delay encompassed peak temperature, weight loss, and onset of clinical signs (Table 1). Shedding of virus into nasal washes was also delayed by approximately one day for each 100-fold reduction in virus dose (Fig. 1). Virus clearance (as determined by lack of detectable infectious virus in nasal wash liquid) was also delayed in ferrets receiving lower doses. With high and medium doses, virus was undetectable in nasal washings by 7 dpi, compared to 10 dpi. By 14–15 dpi, lesions in the nasal cavity were resolving in the mid and high dose groups but some acute inflammation and epithelial necrosis were seen in some animals in the high and low dose groups, however, changes were not seen in 4 out of 4 animals examined in the mid dose group. In the lung, necrotising bronchiolitis was seen in 3 out of 5 animals in the low dose group, and all animals in the mid and high dose groups. Bronchial gland necrosis was seen in all animals in all dose groups. In addition, perivascular oedema was observed in 3 out of 5 animals in the high dose group.

By 5–7 dpi, in the nasal cavity, there was extensive epithelial loss with attenuation of remaining epithelial cells, and marked, suppurative exudation, with similar severity in all animals at all doses. In addition, in 9 out of 9 animals examined at 7 dpi, regenerative changes in the epithelium were observed comprising hyperplasia, and hyperplasia with basophilic cytoplasm. In the trachea, mild changes including mucosal inflammation and glandular necrosis were seen in some animals in the high and low dose groups, however, changes were not seen in 4 out of 4 animals examined in the mid dose group. In the lung, necrotising bronchiolitis was seen in 3 out of 5 animals in the low dose group, and all animals in the mid and high dose groups. Bronchial gland necrosis was seen in all animals in all dose groups. In addition, perivascular oedema was observed in 3 out of 5 animals in the high dose group.

By 14–15 dpi, lesions in the nasal cavity were resolving in the mid and high dose groups but some acute inflammation and epithelial hyperplasia and hyperplasia were still present in the low dose group. In the lower respiratory tract, minimal, resolving changes and mild, residual inflammatory changes were noted in the majority of animals at all doses.

Low dose challenge shows increased sensitivity to treatment with oseltamivir

Since a dose of 10^2 pfu was sufficient to reproducibly induce disease and virus shedding from infected ferrets, the effect of oseltamivir treatment on animals infected with high (10^6 pfu) or low (10^2 pfu) doses of Cal/04 was compared. As a marker of innate immune response to infection immune cells in nasal wash fluid were enumerated (Fig. 3) [34]. Nasal wash cells rose from a baseline of approximately 10^5 cells/ml and reached a similar plateau value of approximately 10^6 cells/ml in both high and low dose infection (Fig. 3, A and B). However the low dose group showed a delay of 1 day compared to the high dose group in reaching maximum concentration. Cell counts in the high dose group were significantly above baseline by 1 dpi ($p<0.05$), whereas in the low dose group cell counts did not rise significantly until 2 dpi. Treatment with oseltamivir had little effect on nasal wash cells in the high dose group and did not depend on whether treatment started before (Fig. 3A) or after (Fig. 3B) infection. However for the low dose group, oseltamivir treatment lead to a delay in the increase of nasal wash cells, with significant reductions in cell counts from treated ferrets on days 2 and 3 post-infection (Figs. 3A and 3B) (Mann-Whitney U-test, $p<0.05$). The effects of oseltamivir treatment on the clinical progress of infection were not statistically significant in the high dose group, but for some parameters were statistically significant in the low dose group, and

![Figure 1. Effect of decreasing infectious dose on virus shedding.](http://example.com/figure1.png)

Low dose challenge leads to delayed, but not reduced, pathological changes in the respiratory tract

Overall the pathological changes observed were similar to previous studies in ferrets using 10^6 pfu [10,11,32] or 10^2 pfu [33] of H1N1pdm09 virus.

At 2 days post-challenge, there was multifocal epithelial necrosis and sloughing, with a mixed, mainly polymorphonuclear inflammatory cell infiltrate, in the nasal cavity of animals that received a dose of 10^6 or 10^4 pfu Cal/04. By contrast, the nasal cavity of the low dose group animals (10^2 pfu), was either normal or contained only a mild, mononuclear cell infiltrate. In the lung, in all dose groups, bronchial inflammatory cell exudation and focal, parenchymal, mononuclear cell infiltrates with a dose dependent increase in severity, were seen in six animals (2 out of 5 animals per group). In addition, variable necrotising bronchiolitis and bronchial gland necrosis were noted between the groups.

By 5–7 dpi, in the nasal cavity, there was extensive epithelial loss with attenuation of remaining epithelial cells, and marked, suppurative exudation, with similar severity in all animals at all doses. In addition, in 9 out of 9 animals examined at 7 dpi, regenerative changes in the epithelium were observed comprising hypertrophy, and hyperplasia with basophilic cytoplasm. In the trachea, mild changes including mucosal inflammation and glandular necrosis were seen in some animals in the high and low dose groups, however, changes were not seen in 4 out of 4 animals examined in the mid dose group. In the lung, necrotising bronchiolitis was seen in 3 out of 5 animals in the low dose group, and all animals in the mid and high dose groups. Bronchial gland necrosis was seen in all animals in all dose groups. In addition, perivascular oedema was observed in 3 out of 5 animals in the high dose group.

By 14–15 dpi, lesions in the nasal cavity were resolving in the mid and high dose groups but some acute inflammation and epithelial hyperplasia and hyperplasia were still present in the low dose group. In the lower respiratory tract, minimal, resolving changes and mild, residual inflammatory changes were noted in the majority of animals at all doses.

Low dose challenge shows increased sensitivity to treatment with oseltamivir

Since a dose of 10^2 pfu was sufficient to reproducibly induce disease and virus shedding from infected ferrets, the effect of oseltamivir treatment on animals infected with high (10^6 pfu) or low (10^2 pfu) doses of Cal/04 was compared. As a marker of innate immune response to infection immune cells in nasal wash fluid were enumerated (Fig. 3) [34]. Nasal wash cells rose from a baseline of approximately 10^5 cells/ml and reached a similar plateau value of approximately 10^6 cells/ml in both high and low dose infection (Fig. 3, A and B). However the low dose group showed a delay of 1 day compared to the high dose group in reaching maximum concentration. Cell counts in the high dose group were significantly above baseline by 1 dpi ($p<0.05$), whereas in the low dose group cell counts did not rise significantly until 2 dpi. Treatment with oseltamivir had little effect on nasal wash cells in the high dose group and did not depend on whether treatment started before (Fig. 3A) or after (Fig. 3B) infection. However for the low dose group, oseltamivir treatment led to a delay in the increase of nasal wash cells, with significant reductions in cell counts from treated ferrets on days 2 and 3 post-infection (Figs. 3A and 3B) (Mann-Whitney U-test, $p<0.05$). The effects of oseltamivir treatment on the clinical progress of infection were not statistically significant in the high dose group, but for some parameters were statistically significant in the low dose group, and
Clinical signs were not observed in the oseltamivir-treated low dose challenge group. A significant reduction in peak temperature of 0.5°C due to therapeutic (but not prophylactic) oseltamivir treatment was observed in the low dose group, but not in the high dose group (Table 2).

Prophylactic and therapeutic oseltamivir treatments also both resulted in a significant reduction in virus shedding only with the low dose challenge (Fig. 2B). There were significant reductions in mean titre at 2 dpi (prophylactic oseltamivir, Fig. 2A, Mann-Whitney U-test, p < 0.05) or 1, 2 and 3 dpi (therapeutic oseltamivir, Fig. 2B). The reduction in mean titre observed in the high dose group at 1 dpi in Fig. 2A was not significant.

Oseltamivir leads to reduced lung virus load only with low dose challenge, and reduced trachea virus load with either challenge dose

In order to further investigate the effects of oseltamivir treatment on ferrets infected with a high or low dose of virus, samples of upper respiratory tract (nasal turbinate) and lower respiratory tract (trachea, lung) were collected for viral load analysis at 1, 2, 4 and 5 dpi. Initial experiments using Cal/04 infection indicated that although significant amounts of infectious virus could be recovered from nasal turbinates (≥10⁷ pfu/g at 2 dpi), recovery from lower respiratory tract tissues was low and variable (data not shown). Hence we opted to determine virus RNA load in tissues by real-time qRT-PCR. Nasal turbinates gave a peak titre on day 1 post-infection for the high dose group (≥10⁹ copies/mg of tissue) and at 2 dpi for the low dose group (≥10⁸ copies/mg of tissue) (Fig. 4A). These timings correspond to the peaks observed in nasal wash virus shedding (Figs. 1 and 2).

In the trachea, peak RNA loads of ≥10⁶ copies/mg were observed by 4 dpi. Both high and low dose groups showed >1000-fold reduction in virus RNA copy number due to oseltamivir at 4 dpi, and 100-300-fold reduction at 5 dpi (Fig. 4B). Noticeably, in the lung tissues of the low dose group, there was a reduction observed at 5 dpi of 100-fold in mean RNA load due to oseltamivir treatment, which was not observed in the high dose group (Fig. 4C). The baseline lung RNA loads observed on day 1 (8/8 ferrets) and day 2 pi (7/8 ferrets) suggest that direct delivery of inoculum to the lung was not a problem in this particular study. One factor in avoiding such a problem is the use of a small inoculum volume (0.2 ml per animal) in this study, as opposed to 0.5–1 ml which is often used in ferret challenge studies. Not all untreated ferrets showed a high lung RNA load by

Table 1. Effect of virus dose on parameters of infection with influenza A/California/04/09.

| Infecting dose (pfu) | 10⁶ | 10⁴ | 10² | mock |
|----------------------|-----|-----|-----|------|
| Day of peak temperature | 2   | 2   | 3   | none |
| Day of greatest weight loss | 2   | 3   | 3   | none |
| Day of maximum nasal wash cell count | 2   | ND  | 3   | none |
| Mean clinical score¹ | 1.48±0.35 | 1.08±0.46 | 0.79±0.07 | 0.00 |
| Day of onset of clinical signs² | 2   | 2   | 3   | none |
| Day of peak virus shedding | 1   | 2   | 2–3 | none |

¹Mean clinical score is calculated as described in Materials and Methods, and expressed as mean score per ferret per day ± standard error of the mean.

²Day of onset refers to median onset of respiratory signs and inactivity from four studies.

ND, not done.

doi:10.1371/journal.pone.0094090.t001
day 5 (2/3 in each of the low dose and high dose groups, for the upper left lobes which were tested), indicating some variability between animals. This variability was also reflected in two ferrets in the high dose, oseltamivir-treated group showing RNA loads of $10^7$ copies/mg at 2 and 3 dpi, respectively, accounting for the greater mean RNA loads in lung on these days (Fig. 4C).

Oseltamivir treatment following low dose challenge, leads to delayed viral-induced pathological changes in the nasal cavity, and reduced changes in the lung.

Pathological changes in the nasal cavity and lung are summarized graphically in Figure 5. In the nasal cavity, significant changes were not observed until 2 dpi. Epithelial loss, necrosis and attenuation; inflammatory cell infiltration and oedema of the propria mucosa; and a suppurative exudate, were present. These changes were more severe (Fig. 5A) in the high dose, oseltamivir-treated group, with decreasing severity in the high and low dose, untreated groups, respectively. Changes were not observed in the low dose, oseltamivir-treated group.

On 4 dpi, similar changes to those described above, and of similar severity to changes in the high dose, oseltamivir-treated and untreated groups, and the low dose, treated group. In 2 animals in the low dose, oseltamivir-treated group, only minimal inflammatory cell infiltration of the propria mucosa was observed (Fig. 6B). Regenerative changes in the surface epithelium, were also observed in the high dose, oseltamivir-treated and untreated groups, and 1 of 2 animals in low dose, untreated group. They were not seen in the low-dose, oseltamivir-treated group.

By 5 dpi, acute and regenerative changes, described above, were observed in all groups and of similar severity.

In the trachea, significant changes were not observed until 4 dpi, and comprised proprial mucosal gland necrosis in only one animal in the high dose, and one animal in the low dose, untreated groups. On day 5 pi, minimal glandular necrosis and mild, inflammatory cell infiltration were observed in 1 animal in the high dose, untreated group. Changes were not observed in the remaining animals in the group, nor any other challenged group.

In the lung, at day 1 pi, changes were generally minimal (Fig. 5B), comprising slight bronchiolar, luminal, inflammatory cell exudation. On day 2 pi, similar exudates were observed in the high dose, treated and untreated groups, with minimal, necrotising bronchiolitis in one animal in the high dose, untreated group. By day 2 pi, similar exudates were observed in the high dose, treated and untreated groups, and the low dose, treated group. In addition, minimal, necrotising bronchiolitis was seen in one animal in the high dose, untreated group. At days 4 and 5 pi, in the untreated groups, changes comprised bronchiolar luminal exudation, parenchymal mononuclear cell infiltration

Table 2. Effect of oseltamivir on clinical parameters following infection with high and low doses of influenza A/California/04/09.

| Effect of oseltamivir on: | Infecting dose (pfu) | 10^6 | 10^2 |
|--------------------------|---------------------|------|------|
| Nasal wash cell count    | Reduction on day 1 or no effect<sup>1</sup> | Delayed rise<sup>1,2</sup>; reduction on days 2<sup>3</sup> and 3<sup>1,2</sup> |
| Weight loss              | No significant effect | No significant effect |
| Peak temperature         | No significant effect | Significant reduction day 3<sup>2</sup> or no effect<sup>1</sup> |
| Clinical score           | No significant effect | Score reduced to zero<sup>2</sup> or no effect<sup>1</sup> |
| Day of onset of clinical signs | No change | No change<sup>1</sup> or no signs<sup>2</sup> |

<sup>1</sup>Prophylactic dose of oseltamivir.
<sup>2</sup>Therapeutic dose of oseltamivir. No effect implies not statistically significant (Mann-Whitney test, p>0.05).

doi:10.1371/journal.pone.0094090.t002
(Fig. 6C), bronchial gland necrosis (Fig. 6C, inset), and peribronchial and perivascular oedema (Fig. 6D). In the untreated groups, these changes were more severe (Fig. 5B). In oseltamivir-treated groups, changes were minimal to mild (Figs. 5B, and 6E, F), and bronchial epithelial and glandular necrosis were not observed. In both treated and untreated groups, there was a slight, dose effect in the frequency of pathological observations.

In the control animals, changes in the nasal cavity, trachea and lung were not observed.

**Discussion**

This study determined the effect of reducing intra-nasal dose of infectious virus on the kinetics of virus shedding and disease progression, and compared the effects of oseltamivir treatment on ferrets infected with a high or low virus dose. Although Cal/04 induces a relatively mild disease in ferrets [9,11,25,33] we were able to reliably infect with 100 pfu via the intra-nasal route (over 50 ferrets infected with this dose in a number of different studies in

---

**Figure 4. Viral RNA loads in ferret respiratory tract tissues.** Ferrets were infected intra-nasally with 10^6 or 10^2 pfu Cal/04 and, where indicated, treated with oseltamivir from 6 hr post-infection. Circles show RNA loads for individual animals. Horizontal lines show group means. Filled circles, no treatment; open circles, oseltamivir treated. A, nasal turbinate; B, trachea; C, lung. High, 10^6 pfu inoculum; Low, 10^2 pfu inoculum. Samples were taken from 2 ferrets on days 1 to 4, and 3 ferrets on day 5. The sensitivity of the assay was approximately 10^3 copies/mg.

doi:10.1371/journal.pone.0094090.g004

**Figure 5. Summary of severity of pathological changes in untreated or oseltamivir treated ferret tissues.** A, Nasal cavity, B, lung. In each case, changes were scored as minimal (min), mild, moderate (mod), or marked, and were summed for each group of ferrets on each day post-infection. Group size was 2 ferrets, except day 5 which was groups of 3 ferrets. The day 5 summed frequencies have been normalised to facilitate comparison to the other days.

doi:10.1371/journal.pone.0094090.g005
this laboratory have all sero-converted, shed virus in nasal washes, and shown clinical signs of disease. The most reproducible early sign of infection (other than virus shedding) was the innate immune cell count in nasal washes which typically rose 100-fold following infection and is consistent with previous data [34]. During influenza virus infection the nasal cavity cell population comprises mostly neutrophils and monocytes/macrophages, and represents activation of the innate immune system [28]. We observed that a reduction of 10,000-fold in virus inoculum (from $10^6$ pfu to $10^2$ pfu) led to a delay of 1 day in reaching peak cell count, suggesting a slower progression of the innate immune response when using the $10^2$ pfu challenge dose. Taken as a whole, the spectrum of clinical signs (including temperature rise, transient weight loss, sneezing, nasal discharge and inactivity) was clearly observed in the present study following inoculation with $10^2$ pfu Cal/04, and was only modestly reduced compared to a $10^6$ pfu inoculation. The most noticeable effect of using the lower dose was the delayed kinetics of infection, rather than any major amelioration of disease. A previous study by Smith et al compared doses of $10^5$ and $10^2$ pfu Cal/04 in ferrets, however no obvious clinical signs were observed in that study [33]. In agreement with the present study Smith et al showed a delay in peak virus shedding in the lower dose group, but nasal washes were not taken every day and therefore the studies are not directly comparable [33]. A novel observation made in the present study is that lowering the challenge dose does not lead to lower virus shedding, but leads to increased shedding both in terms of total virus shed over the course of the infection, and peak titre of shed virus. We hypothesise that the slower innate immune response associated with the lower virus challenge, as described above, allows
increased virus accumulation in the nasal cavity. The trend towards increased peak virus titre with lower challenge dose is also shown in Figure 1 of Smith et al., although the authors did not highlight the observation [35].

We previously reported a low intra-nasal dose to demonstrate the efficacy of oseltamivir in ferrets against influenza virus 244 in the ferret model [26,27]. Here, oseltamivir was used as a test treatment with both high and low doses of Cal/04, as oseltamivir was used extensively in humans during the 2009 pandemic, and previous studies have demonstrated oseltamivir efficacy in ferrets against a number of influenza virus strains [12,19,20,26]. Using nasal wash cell count and virus titre as measures of infection, it was noted that oseltamivir treatment had little effect on either measure following infection with 10^6 pfu. A previous study [12] which used a 10^5 pfu Cal/04 challenge did show reductions in nasal wash cell counts (but not virus shedding), but used a substantially higher dose of oseltamivir than the human-equivalent doses used here. However, in the present study, nasal wash cell count showed a delayed rise due to oseltamivir treatment (commenced before or after virus inoculation) following infection with 10^5 pfu Cal/04. Similarly, virus titres showed significant reductions in response to oseltamivir treatment following infection with 10^5 pfu Cal/04. Furthermore, only the 10^7 pfu-infected, oseltamivir-treated animals showed a reduction in lung viral RNA load at 5 dpi and a reduction in pathological changes in the nasal cavity at 4 dpi. In the experiment in which the therapeutic dose of oseltamivir was used (10 mg/kg/day), no nasal signs (sneezing, nasal discharge) were observed at all in the treated 10^5 pfu group. An unexpected finding was an increase in severity of changes in the nasal cavity in the high dose, oseltamivir-treated group, compared with the untreated, high and low dose groups. Whether this represented some animal or challenge variation could not be determined. However, these differences had disappeared by day 4 when the most severe changes were observed in the untreated, high-dose group. The effect of oseltamivir treatment on the virus-induced pathological changes was more clearly observable in the low dose group, in particular a delay in changes in the nasal cavity from 2 to 5 dpi.

The rate of virus clearance did not benefit from oseltamivir treatment, as virus shedding in oseltamivir-treated ferrets is higher than in untreated ferrets at 6 dpi in both high and low dose challenge groups (Figure 2A). This lack of improvement of clearance kinetics has been observed before [26], and is thought to be due to viral rebound following cessation of treatment at 3 dpi.

In summary, while oseltamivir treatment was of limited efficacy in the high dose challenge (10^7 pfu) model (with reduction of virus shedding at 1 dpi; reduction of trachea viral RNA load on 4–5 dpi; reduction of lung pathology at 4–5 dpi), it was highly effective with the low dose (10^5 pfu) model.

Although oseltamivir treatment has previously been noted to reduce influenza virus load in ferret lung tissue [19], to our knowledge this is first study to show the dramatic ~2000- to 5000-fold reduction in virus RNA load in the trachea at 4 dpi. One day later on day 5, RNA loads in the trachea were clearly above background in at least some treated animals (Fig.6 4B), and viral RNA was also detectable in the lungs of most animals (Fig.6 4C). These data suggest that oseltamivir is effective in slowing the passage of the Cal/04 virus down the respiratory tract, regardless of virus dose. It should be noted that sample sizes were too small to estimate statistical significance of these findings. A future study using larger sample sizes should be conducted to investigate further the effects of oseltamivir on viral RNA load in the ferret respiratory tract.

We conclude that the low dose (10^5 pfu Cal/04 virus) ferret model leads to improved sensitivity in demonstrating the efficacy of oseltamivir, and thus may be valuable in the future for the study of influenza therapeutics and vaccines.

Acknowledgments

The authors would like to thank the staff of the Biological Investigations Group at PHE, Porton for their technical expertise in conducting the animal experiments; Graham Hall, Kim Hatch and Laura Hunter for processing histopathology samples, and Philippa Spencer (DSTL) for statistical advice. This report includes work commissioned by the National Institute of Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute of Health Research, or the Department of Health.

Author Contributions

Conceived and designed the experiments: BKD CB EN WSB NJD AJE BH NJS MWC. Performed the experiments: ACM BKD CJW KAR TJB ER GP IT SD JP. Analyzed the data: ACM BKD CB ER GP NJS. Wrote the paper: ACM BKD CB ER GP NJD MWC.

References

1. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605–2615.
2. Smith GJ, Voigtlaender D, Balh J, Lynch SJ, Worobey M, et al. (2009) Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459: 1122–1125.
3. Donaldson Ll, Rutter PD, Ellis BM, Greaves FE, Myton OT, et al. (2009) Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 339: i5213.
4. Pemble RG, McLean E, Zhao H, Cleary P, Bracebridge S, et al. (2010) Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro Surveill: pii: 19571.
5. Dawood FS, Bolano AD, Reeder C, Meltzer MI, Shay DK, et al. (2012) Estimating global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12: 678–695.
6. Matsuda Y, Lamandre EW, Subbarao K (2009) The ferret model for influenza. Curr Protoc Microbiol Chapter 15: Unit 15G 12.
7. Bodewes R, Rimmelzwaan GF, Osterhaus AD (2010) Animal models for the transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: 484–487.
8. Kirkeby S, Martel CJ, Aasted B (2009) Infection with human H1N1 influenza virus affects the expression of sialic acids of metabolic mucous cells in the ferret airways. Virus Res 814: 225–232.
9. Maines TR, Jayaraman A, Beher JA, Wadford DA, Pappas C, et al. (2009) Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: 484–487.
10. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, et al. (2009) Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325: 481–483.
11. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1012–1025.
12. Govorkova EA, Marathe BM, Prevost A, Rehg JE, Webster RG (2011) Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res 91: 81–88.
13. Killingby L, Ensonte J, Booy R, Hayward A, Oxford J, et al. (2011) Potential role of human challenge studies for investigation of influenza transmission. Lancet Infect Dis 11: 879–890.
14. Aldor RH, Kased JA, Gerone PJ, Knight V (1966) Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med 122: 800–804.
15. Gustin KM, Belsier JA, Wadford DA, Pearce MB, Katz JM, et al. (2011) Influenza virus aerosol exposure and analytical system for ferrets. Proc Natl Acad Sci U S A 108: 8432–8437.
16. Mishin VP, Nedialkova MS, Hayden FG, Gabareva LV (2005) Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. Vaccine 23: 2922–2927.
17. Suguitan AL, Zengel JR, Jacobson S, Gee S, Cetz J, et al. (2013) Influenza H1N1 pdm-specific maternal antibodies offer limited protection against wild-type influenza A virus in a ferret model. Vaccine 23: 2922–2927.
18. Drummond NJ, Marriott AC (2006) In vivo antiviral activity: defective interfering virus protects against virulent influenza A virus than avirulent virus. J Gen Virol 87: 1259–1265.
19. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, et al. (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51: 1414–1424.

20. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, et al. (1998) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42: 640–646.

21. Sweet C, Jakeman KJ, Bush K, Wagaman PC, McKown LA, et al. (2002) Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother 46: 996–1004.

22. Ryan DM, Ticehurst J, Dempsey MH (1995) GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 39: 2583–2584.

23. Boltz DA, Rehg JE, McClaren J, Webster RG, Govorkova EA (2008) Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J Infect Dis 197: 1315–1323.

24. CDC (2009) Swine influenza A (H1N1) infection in two children—Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep 58: 400–402.

25. Lednicky JA, Crouth CR, Lawrence SJ, Hamilton SB, Daniels DE, et al. (2010) A nonlethal young domesticated ferret (Mustela putorius furo) model for studying pandemic influenza virus A/California/04/2009 (H1N1). Comp Med 60: 364–368.

26. Dimmock NJ, Dove BK, Meng B, Scott PD, Taylor I, et al. (2012) Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antiviral Res 96: 376–385.

27. Dimmock NJ, Dove BK, Scott PD, Meng B, Taylor I, et al. (2012) Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established. PLoS One 7: e49394.

28. Chen K-S, Bhajar SS, King EC (1995) Induction and relief of nasal congestion in ferrets infected with influenza virus. Int. J Exp Path 76: 55–64.

29. Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55 Suppl 1: i5–i21.

30. Slomka MJ, Densham AL, Coward VJ, Essen S, Brooks SM, et al. (2010) Real time reverse transcription (RT)-polymerase chain reaction (PCR) methods for detection of pandemic (H1N1) 2009 influenza virus and European swine influenza A virus infections in pigs. Influenza Other Respi Viruses 4: 277–295.

31. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, et al. (2002) Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H3 and H7 hemagglutinin subtypes. J Clin Microbiol 40: 3256–3260.

32. van den Brand JM, Stittelaar KJ, van Amerongen G, Rimmelzwaan GF, Simon J, et al. (2010) Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J Infect Dis 201: 993–999.

33. Smith JH, Nagy T, Driskell E, Brooks P, Tompkins SM, et al. (2011) Comparative pathology in ferrets infected with H1N1 influenza A viruses isolated from different hosts. J Virol 85: 7572–7581.

34. Reuman PD, Keely S, Schiff GM (1989) Assessment of signs of influenza illness in the ferret model. J Virol Methods 24: 27–34.